Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status

References

• Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824–830.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343–3356.
   PubMed Web of Science ®Google Scholar
• Goldman JM, Melo JV. Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med 2003;349: 1451–1464.
   PubMed Web of Science ®Google Scholar
• Foo J, Drummond MW, Clarkson B, . Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 2009;5:e1000503.
   Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, . Stem cells, cancer, and cancer stem cells. Nature 2001;414:105–111.
   PubMed Web of Science ®Google Scholar
• Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005;15:494–501.
   PubMed Web of Science ®Google Scholar
• Lucas CM, Wang L, Austin GM, . A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008;22:1963–1966.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, . Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.
   PubMed Web of Science ®Google Scholar
• Peggs K, Mackinnon S. Imatinib mesylate–the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348: 1048–1050.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Brand R, Apperley J, . Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica2006;91: 513–521.
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, . Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319–325.
   PubMed Web of Science ®Google Scholar
• Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010;101:1577–1581.
   PubMed Web of Science ®Google Scholar
• Hu Y, Chen Y, Douglas L, . beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009;23:109–116.
   PubMed Web of Science ®Google Scholar
• Ito T, Kwon HY, Zimdahl B, . Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010;466:765–768.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med 2009;361:2094–2096.
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, . Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457–1461.
   PubMed Web of Science ®Google Scholar
• Rohatgi R, Scott MP. Patching the gaps in Hedgehog signalling. Nat Cell Biol 2007;9:1005–1009.
   PubMed Web of Science ®Google Scholar
• Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet 2006;7:841–850.
   PubMed Web of Science ®Google Scholar
• Dierks C, Beigi R, Guo GR, . Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008;14:238–249.
   PubMed Web of Science ®Google Scholar
• Zhao C, Chen A, Jamieson CH, . Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776–779.
   PubMed Web of Science ®Google Scholar
• Duman-Scheel M, Weng L, Xin S, . Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature 2002;417:299–304.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Martinelli G, Rosti G, . Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 2004;104:4245–4251.
   PubMed Web of Science ®Google Scholar
• Ballestrero A, Cirmena G, Dominietto A, . Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. Int J Lab Hematol 2010;32: 387–391.
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, . Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374–7379.
   PubMed Web of Science ®Google Scholar
• Bouzar AB, Boxus M, Defoiche J, . Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009;144:41–52.
   PubMed Web of Science ®Google Scholar
• Mason KD, Khaw SL, Rayeroux KC, . The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009;23: 2034–2041.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
   PubMedGoogle Scholar
• Deguchi Y, Kimura S, Ashihara E, . Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 2008;32:980–983.
   PubMed Web of Science ®Google Scholar
• Kim J, Tang JY, Gong R, . Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010;17:388–399.
   PubMed Web of Science ®Google Scholar
• Kim J, Lee JJ, Gardner D, . Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA 2010;107: 13432–13437.
   PubMed Web of Science ®Google Scholar
• Long B, Zhu H, Zhu C, . Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients. J Exp Clin Cancer Res 2011;30:8.
   PubMed Web of Science ®Google Scholar
• Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, . Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 2010;29:6314–6322.
   PubMed Web of Science ®Google Scholar
• Deininger MW, O’Brien SG, Ford JM, . Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637–1647.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–2249.
   PubMed Web of Science ®Google Scholar
• Hasford J, Ansari H, Pfirrmann M, . Analysis and validation of prognostic factors for CML. German CML Study Group. Bone Marrow Transplant 1996;17(Suppl. 3):S49–S54.
   Google Scholar
• Hehlmann R, Ansari H, Hasford J, . Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group. Br J Haematol 1997;97:76–85.
   PubMed Web of Science ®Google Scholar
• Mohty M, Yong AS, Szydlo RM, . The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007;110:380–383.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973–988.
   PubMed Web of Science ®Google Scholar
• Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010;101:1577–1581.
   PubMed Web of Science ®Google Scholar
• Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program 2009:453–460.
   PubMedGoogle Scholar